GENinCode has provided a traded update for the 6-months to June 2025. Revenues for the period grew 15% to £1.6m, driven by all three targeted regions. Gross margin remained strong at 53% and the loss for the period of £2.4m was in-line with 1H24A. Cash at the end of 1H25 was £2.4m, supported by on-going cost controls and a successful equity raise of £4.1m, gross. For the second half we expect the company to make progress on commercialising its tests in the US, expand UK LIPID inCode into new NHS ....
